Sector: Life Sciences

Latest content

Moderna on IP collision course with US government

The company is at loggerheads with National Institutes of Health over inventorship of crucial covid vaccine technology

11 November 2021

Dim prospects for industry 101 compromise as US Congress looks at eligibility once more

People involved in previous reform efforts say that passing any legislation will be tough as stakeholders are still years away from agreement

09 November 2021

Generics are the winners as CAFC doubles down on strict Hatch-Waxman venue selection criteria

A decision handed down last Friday against Celgene elaborates on the rules set out in the landmark Valeant case and makes life tough for pharma patent owners

09 November 2021

Patent system should address “blind spot” around AI-generated inventions, KIPO commissioner says

In an exclusive interview with IAM, Kim Yong Rae says innovation will be discouraged if law fails to keep pace with technological change

09 November 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum

05 November 2021

European plausibility uncertainties could be cleared up by new Enlarged Board of Appeal referral

The EPO is seeking clarity on a crucial question facing patentees, but not everyone is sure that a recent referral is the best vehicle

04 November 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine

02 November 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales

01 November 2021

Biosimilars IP playbook is being re-written by the rise of interchangeables

Landmark designations highlight strategic IP ramifications of automatically-substitutable biosimilars

28 October 2021

Covid-19 patent disputes highlight safe harbour uncertainties for research tool innovators

Allele Therapeutics’ suits against Pfizer and Regeneron could have big implications for the extent to which platforms can monetise IP

26 October 2021

Get unlimited access to all IAM content